GMAB - genmab.com Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Genmab A/S (GMAB)

Flawless temperature-controlled antibody transportation ensures the timely delivery of medications. However, geopolitical tensions create risks for patenting and supply chains. A PEG ratio analysis helps assess these factors, where the 1.59 mark records this metric. The capital of Genmab A/S (GMAB) is based on royalty payments from pharma behemoths implementing innovative targeted developments.

GMAB: genmab.com Price/Earnings to Growth Multiple 07/04/2022 - 11/10/2026

Metric breakdowns and analytics for Genmab A/S (GMAB)

- market value and analyst target forecast:
Price Rate Chart Genmab AS|GMAB - Consensus Target
- market capitalization statistics:
Market Value Genmab US|GMAB - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share Genmab|GMAB - Company Net Assets|Market Cap to Book Value Multiple genmab.com|GMAB - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Genmab A/S|GMAB - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital genmab.com|GMAB - Company Aggregate Debts|Debt to Net Assets Genmab US|GMAB - Company Long-Term Debts|Short-Term Debt Genmab|Intermediate Liquidity Ratio genmab.com
- earnings and valuation multiples information:
GMAB - Net Profit|Expected Net Profit Genmab A/S|GMAB - P/E Multiple|Price to Future Earnings Ratio Genmab Corp|GMAB - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Genmab US|GMAB - Operating profit before deduction of amortization|Earnings per share for the last four quarters Genmab|GMAB - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months genmab.com|GMAB - Earnings growth in current year|Expected net earnings per share growth next year Genmab A/S
General company analysis:Genmab A/S
Signature product of genmab.com

The unique targeted antibody platform of Genmab A/S ensures strong pricing power through premium pharmaceutical partner contracts. This metric correlates the stock's market value with earnings growth rates, determining the cost of a unit of business expansion adjusted for fiscal expenses. PEG ratio values below one signal that the asset is undervalued relative to its potential, highlighting the most promising entry points.

Competing companies

Exelixis Inc (EXEL) - Price to Net Income Growth Ratio|Nuvalent Corp - Price/Earnings to Growth Multiple|Kymera Corp (KYMR) - Price to Earnings Adjusted for Growth Rate|IDYA: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ELVN (enliventherapeutics.com)|ORIC (ORIC Pharmaceuticals, Inc.) - Price/Earnings to Growth Multiple|RLAY: Company Value to Earnings Growth Ratio|NRIX (Nurix Pharma) - PEG Multiple|PEG Multiple Tyra Corp|Price/Earnings to Growth Ratio Verastem, Inc. (VSTM)|GLUE (monterosatx.com) - Growth-Adjusted Payback Ratio|PEG Multiple CGEM (Cullinan Therapeutics, Inc.)|Price to Net Income Growth Ratio Immuneering Corp|C4 Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Black Diamond Therapeutics, Inc|RPTX (Repare Therapeutics) - Price/Earnings to Growth Multiple|PMVP: Company Value to Earnings Growth Ratio|KPTI (Karyopharm Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Propanc Biopharma, Inc. PPCB|PEG Multiple BGMS|aadibio.com - Growth-Adjusted P/E Ratio|Aileron Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BPMC|GLYC: Price/Earnings to Growth Multiple|SpringWorks Therapeutics Inc. - Company Value to Earnings Growth Ratio